Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
16 May 2024
|
|
N 14:41 | Leniolisib 3 changes history +359 [Alen Antony (3×)] | |||
|
|
14:41 (cur | prev) +2 Alen Antony talk contribs | ||||
|
|
14:40 (cur | prev) −2 Alen Antony talk contribs | ||||
| N |
|
14:40 (cur | prev) +359 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}") | |||
|
|
14:34 | Trofinetide 6 changes history +5,945 [Alen Antony (6×)] | |||
|
|
14:34 (cur | prev) +1,803 Alen Antony talk contribs | ||||
|
|
14:19 (cur | prev) −1 Alen Antony talk contribs Tag: Manual revert | ||||
|
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs | ||||
|
|
N 10:15 | Avacincaptad pegol 2 changes history +3,387 [Muhammad Waleed (2×)] | |||
|
|
10:15 (cur | prev) +132 Muhammad Waleed talk contribs | ||||
| N |
|
10:11 (cur | prev) +3,255 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...") | |||
|
|
10:14 | Talquetamab-tgvs 2 changes history +2,312 [Muhammad Waleed (2×)] | |||
|
|
10:14 (cur | prev) +505 Muhammad Waleed talk contribs | ||||
|
|
09:28 (cur | prev) +1,807 Muhammad Waleed talk contribs | ||||
| 09:31 | Upload log Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey) | ||||
.png){kind=link}
|
|
07:07 | User:AED 4 changes history +102 [Alara E. Dagsali (4×)] | |||
|
|
07:07 (cur | prev) +21 Alara E. Dagsali talk contribs | ||||
|
|
06:42 (cur | prev) +24 Alara E. Dagsali talk contribs | ||||
|
|
06:33 (cur | prev) +27 Alara E. Dagsali talk contribs | ||||
|
|
06:22 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
|
|
N 07:06 | Diclofenac Patch 2 changes history +48,613 [Alara E. Dagsali (2×)] | |||
|
|
07:06 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
07:06 (cur | prev) +48,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...") | |||
|
|
N 06:42 | Cortisone Acetate 2 changes history +14,098 [Alara E. Dagsali (2×)] | |||
|
|
06:42 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:42 (cur | prev) +14,095 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...") | |||
|
|
N 06:33 | Clocortolone Pivalate 2 changes history +4,446 [Alara E. Dagsali (2×)] | |||
|
|
06:33 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:32 (cur | prev) +4,443 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...") | |||
|
|
N 06:21 | Scorpion 2 changes history +12,448 [Alara E. Dagsali (2×)] | |||
|
|
06:21 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
| N |
|
06:20 (cur | prev) +12,418 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...") | |||
15 May 2024
|
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
|
20:43 (cur | prev) +535 Badgettrg talk contribs | ||||
| 14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs | ||||
|
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") | |||
|
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
|
04:40 (cur | prev) +135 Alen Antony talk contribs | ||||
|
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
|
01:09 (cur | prev) +59 Alen Antony talk contribs | ||||
|
|
m 03:31 | Non-degenerate nucleotides per response element 2 changes history −129 [Marshallsumter (2×)] | |||
| m |
|
03:31 (cur | prev) −3 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
03:27 (cur | prev) −126 Marshallsumter talk contribs (→Tabulation of counts) | |||
14 May 2024
| 23:18 | User:Archana.vajjala diffhist −4 Archana.vajjala talk contribs | ||||
|
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
|
21:34 (cur | prev) +94 Alen Antony talk contribs | ||||
|
|
m 20:44 | Non-degenerate nucleotides per response element 2 changes history +391 [Marshallsumter (2×)] | |||
| m |
|
20:44 (cur | prev) +391 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
20:07 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||